Why the Old Data Team Model Breaks in 2027

For most of the past decade, the default pharma data team looked something like this: a director of analytics, a handful of business analysts writing SQL against a data warehouse, one or two data scientists building models in isolation, and an IT-owned data engineering group focused on ETL pipelines to source systems. This model worked well enough when the primary demand on the team was descriptive reporting, occasional forecasting, and periodic support for a market access or medical affairs project. It does not work in 2026, and it will fail hard by 2027.

The reasons are structural. First, the surface area of data work has expanded dramatically. Pharma data teams are now expected to support clinical operations, regulatory intelligence, commercial analytics, real-world evidence, manufacturing quality, safety and pharmacovigilance, medical affairs, and increasingly patient-facing digital products. Each of these domains has its own data models, regulatory constraints, and stakeholder expectations. A single centralized generalist team cannot credibly serve all of them, and yet each domain team acting alone creates duplication, inconsistency, and audit risk.

Second, the AI shift is not incremental. Deloitte’s 2026 Life Sciences Outlook found that only 22 percent of life sciences leaders have successfully scaled AI, and just 9 percent report meaningful returns, but 64 percent plan to increase AI investments over the next two years.1 Meanwhile, 78 percent of technology leaders anticipate broad integration of AI agents into architecture workflows within five years. Teams built for descriptive analytics do not have the muscle to operationalize dozens of models under GxP-adjacent constraints. New roles and new operating patterns are required.

Third, the talent economics have flipped. In 2018, most pharma data teams were competing primarily with each other and with a small number of tech-adjacent players for talent. In 2026, they are competing with hyperscalers, foundation model labs, and every mid-cap enterprise that has convinced itself it needs an AI strategy. About 70 percent of pharma hiring managers now report difficulty finding candidates with both deep pharmaceutical knowledge and AI skills, and McKinsey has described the “AI translator” who bridges domain and technical fluency as being in particularly short supply.2 The old model of hiring generalist analysts and hoping they self-develop into modern practitioners is no longer viable.

22% of life sciences leaders have successfully scaled AI as of 20261
70% of pharma hiring managers cite difficulty finding AI + domain hybrids2
50% projected gap between US data science demand and supply3

The fourth reason the old model breaks is regulatory. The EMA’s reflection paper on AI in the medicinal product lifecycle, adopted in late 2024, made clear that AI systems supporting regulated decisions require documented data governance, validated pipelines, and lifecycle oversight.4 This is not something an analyst pool can shoulder as an afterthought. It requires dedicated capability, someone whose job title is not “data scientist” but “AI governance specialist” or equivalent. Organizations that try to bolt governance onto an already-overloaded analytics team will produce brittle, non-defensible AI programs.

The Emerging Roles That Now Matter

Five roles are reshaping how pharma data teams are structured. None of these existed as widespread job titles in the industry five years ago. All of them now show up in job postings across top-20 pharma and mid-cap biotech. Leaders who understand what each role does, and where it sits in the team topology, are better positioned to hire and design their organizations effectively.

Analytics Engineer

The analytics engineer sits between the data engineer and the analyst. Where a data engineer moves raw data from source systems into a warehouse, and an analyst answers business questions from curated tables, the analytics engineer owns the transformation layer in between, the semantic models, the metric definitions, the dbt-style transformations, and the tests that make sure the numbers agree. This role emerged from the modern data stack world and has been rapidly absorbed into pharma because it directly addresses one of the most persistent complaints in the industry: that two dashboards showing the same KPI report different numbers.

In practice, analytics engineers in pharma design scalable data models, build automated ETL pipelines, and collaborate across teams to ensure that metric definitions are consistent from clinical operations to commercial performance reporting.5 They also carry a significant share of the data quality workload, in effect, they are the quality assurance function for the analytical estate. Many pharma organizations underinvest in this role and pay for it later in reconciliation cycles and audit findings.

ML Platform Engineer

The ML platform engineer builds the shared infrastructure that lets data scientists and ML engineers deploy models reliably. This is not the same as a general SRE or DevOps engineer. ML platform engineers understand model registries, feature stores, training pipelines, model monitoring, and the specific tooling required to run experiment tracking at scale. In pharma, they also need to understand how validated environments differ from research environments, and how to build platform capabilities that satisfy both.

The reason this role has become critical is simple: without a platform, every model becomes a snowflake. Data scientists spend most of their time on infrastructure work rather than on modeling. Deployment becomes a bespoke exercise, and each model becomes a compliance liability because there is no consistent pattern to audit against. A well-built ML platform lets a team of ten data scientists ship more models than a team of twenty-five without one.

Data Product Manager

The data product manager treats internal data assets as products with users, backlogs, roadmaps, and SLAs. This role is distinct from the pharma marketing product manager who owns a drug brand, and it is distinct from the software product manager on a commercial platform. The data product manager owns things like the RWE data mart, the clinical KPI layer, the safety signal detection model, or the reg intelligence knowledge base as durable, versioned products rather than one-off deliverables.

The essential shift is orientation. Where a project delivers something and then disbands, a product persists, and someone is accountable for its ongoing value. Data product managers coordinate cross-functionally with R&D, medical affairs, regulatory affairs, and commercial teams to ensure their products meet real user needs, and they own the analytics used to evaluate whether the product is delivering the intended outcome.6 Pharma organizations that adopt this model report noticeably higher user satisfaction with data assets, because someone finally owns the whole lifecycle.

MLOps Engineer

The MLOps engineer operates ML models in production. This overlaps with the ML platform engineer but is more focused on the operational side: deployment pipelines, drift monitoring, retraining triggers, model rollback, and incident response for model failures. In pharma, MLOps engineers must also understand how model changes intersect with validation status, which change control processes apply, and how to log evidence for regulatory review.

Demand for this role has grown sharply. Otsuka America Pharmaceutical, among others, has been recruiting senior MLOps engineers, and industry compensation trackers show mid-level MLOps engineers with life sciences experience earning between roughly $130,000 and $180,000 base in the US, with senior specialists commanding more.7 In Europe, mid-level pharma MLOps salaries run €70,000 to €90,000, with senior roles in Switzerland, Germany, and the Netherlands crossing €100,000.7

AI Governance Specialist

The AI governance specialist is the newest role in the portfolio, and the one most likely to be underweighted in current org designs. This role owns the policies, controls, model risk assessments, and documentation that make an AI program defensible to internal audit and external regulators. It is not a data scientist role, and it is not a compliance officer role. It sits between them, translating regulatory expectations into practical model governance and translating model realities into audit-ready evidence.

Only a few top-20 pharmas, including Pfizer, Lilly, and Merck, have appointed formal Chief AI Officers at the C-suite level.8 Most organizations instead run AI governance through a steering committee supported by one or more governance specialists embedded in the data team or in risk. The role is increasingly listed on major job boards, with Indeed showing hundreds of open AI governance postings in pharma and biotech.9

The Sakara Digital perspective. When we advise pharma leaders on data team design, we consistently see governance underinvested relative to platform and product roles. The bias is understandable, governance work is less visible day to day and does not directly ship features. But under Annex 22, EMA reflection paper expectations, and increasingly explicit FDA scrutiny of AI-supported decisions, an ungoverned model portfolio is a warning letter waiting to happen. Hire the governance role earlier than feels comfortable.

Right-Sized Ratios by Company Stage

The right size for a pharma data team varies enormously by company stage, therapeutic focus, and commercial footprint. That said, benchmark ratios do exist, and leaders should understand them before setting headcount plans. The three archetypes below cover the majority of the pharma landscape.

Series B Biotech (approximately 50 to 150 total employees)

A Series B biotech typically has fifty to a hundred and fifty total employees and needs a data function that punches well above its weight. Successful Series B companies commonly triple to quintuple total headcount between Series A and B while maintaining or improving revenue-per-employee metrics.10 Investors expect specialized functional leaders reporting to the CEO by Series B, and the data function is not exempt.

A realistic staffing target for a Series B biotech is between four and eight data-specific roles. This usually looks like one data platform lead (playing both engineer and architect), two analytics engineers or data engineers, one or two data scientists focused on the most valuable use case (often clinical development analytics or biomarker discovery), one bioinformatics or computational biology specialist depending on the therapeutic focus, and either a shared data product manager or a data function lead who covers product responsibilities as part of the leadership role. Governance is typically owned by the head of quality or by a fractional advisor at this stage. There is not yet enough model portfolio to justify a full-time governance specialist.

Mid-Cap Pharma (approximately 1,000 to 15,000 employees)

Mid-cap pharma organizations, running a few marketed products, an active development pipeline, and commercial operations across multiple geographies, have both the complexity and the resources to build proper multi-layered data teams. A realistic total data function size at this stage is between forty and one hundred and twenty full-time equivalents, though this varies dramatically based on how much analytics work is retained in-house versus delivered by external partners.

The typical shape at mid-cap includes a central data platform team of eight to fifteen people, embedded analytics engineers and data scientists in each major business domain (commercial, clinical, medical, manufacturing, safety), a shared ML platform and MLOps team of five to ten, at least two dedicated AI governance specialists, three to five data product managers each owning a portfolio of internal data products, and central data governance and stewardship spanning another five to ten people. Reporting lines are often hybrid, with domain analysts reporting to business units, and platform, MLOps, and governance reporting to a central CDO or Chief Digital Officer function.

Large Pharma (15,000+ employees, top-20)

Large pharma data functions can exceed one thousand data-specialized full-time equivalents when counting everyone from bioinformaticians in R&D through commercial analytics teams. At this scale, the question is not how many people to hire but how to organize them so they do not accidentally build the same thing three times. The most effective large-pharma models use a data mesh or hub-and-spoke pattern, with strong central platform and governance capability and domain-embedded analytics teams that own their data products.

Reporting structures at this scale are almost always hybrid or federated. Deloitte and others have reported that 48 percent of life sciences and health care executives feel their board lacks representation in AI and data science, which puts pressure on senior data leadership to serve both operational and governance functions.1 Large pharma data leaders spend an outsized share of time on standards, capability building, and cross-domain coordination rather than on directly running teams.

4-8 data roles at Series B biotech (of ~100 total employees)
40-120 data FTEs at mid-cap pharma (1K to 15K employees)
1,000+ data-specialized FTEs at top-20 large pharma

Reporting Structures: Centralized, Federated, Hybrid

The reporting structure debate has been running in pharma data circles for a decade, and it is not going to be settled in this article. What we can offer is a clearer framing of the trade-offs and a decision framework that reflects how the best-performing organizations actually operate.

Centralized

Under a centralized model, all data-related functions and responsibilities are consolidated under a single authority, typically a Chief Data Officer or Chief Digital and Data Officer.11 This model is a natural fit for highly regulated industries like pharma because it produces unified policy enforcement, a clear audit trail, and consistent metric definitions. Where centralization is properly implemented, reporting discrepancies drop dramatically. The trade-off is speed. A centralized team can become a bottleneck for domain teams that need rapid iteration on domain-specific problems, and business partners can start to feel like they are queuing for attention rather than being served.

Federated

Under a federated model, data teams are embedded in business domains, each owning its own data products, models, and analytics.12 This model is often paired with data mesh architecture, where domain teams also own the underlying data products they publish for others to consume. Federated models fit multinational pharma groups with distinct regional or franchise operations, and they let domain teams move quickly on their own priorities. The failure mode is inconsistency and duplication. Without strong federated governance, two commercial analytics teams can build competing customer segmentations, three RWE teams can build overlapping data marts, and no one can produce a single, trusted enterprise KPI.

Hybrid

The hybrid model, which most successful mid-cap and large pharma organizations end up adopting, keeps platform, governance, and shared standards central while embedding analytics engineers, data scientists, and MLOps into business domains.13 In this model, core data elements like master data, product hierarchies, and enterprise KPIs are centrally defined, while domain teams have autonomy over their specific analytical models and dashboards. The hybrid model requires more organizational discipline than either extreme, but it aligns with how modern data mesh implementations actually work in pharma.14

CENTRALIZED

Best for smaller organizations and highly regulated single-purpose functions

Strong governance, consistent metrics, defensible audit trail. Risk: bottleneck for domain teams; can feel unresponsive to business partners.

FEDERATED

Best for multinational pharma with distinct franchises or regions

Speed and domain fit; teams own their outcomes. Risk: metric drift, duplication, and inconsistent governance if not carefully coordinated.

HYBRID

Best for mid-cap and large pharma with mixed use cases

Central platform and governance, embedded analytics and MLOps in domains. Requires organizational discipline but scales best.

DATA MESH

Best for organizations with mature engineering capability

Domain-owned data products with federated governance. High long-term leverage; steep initial platform investment; incremental adoption pattern recommended.

Skills That Matter Now vs. Two Years Out

Because job titles change slowly relative to actual work, it is useful to look at the underlying skills that pharma data leaders should hire for, both today and looking two years out. IQVIA’s 2026 themes for life sciences data and analytics emphasize connected strategies, strong governance, practical AI adoption, and enterprise foundations that support scale.15 These themes translate directly to skill priorities.

Skills That Matter Now (2026)

  • Data modeling and metric definition. The ability to define shared dimensions, hierarchies, and KPIs in ways that survive contact with real business use is more valuable than raw modeling skill.
  • Pipeline engineering with governance awareness. Anyone building production pipelines needs to understand data lineage, change control, and how their pipeline sits in a validated system landscape.
  • Applied ML with production discipline. Fewer notebook experiments, more deployed models with monitoring and retraining plans. Model discipline is now the differentiator.
  • Domain fluency in at least one therapeutic or functional area. The “translator” role is real. Domain fluency separates useful data practitioners from expensive commodity ones.
  • Regulatory literacy. Practitioners need to understand at least the basics of GxP, 21 CFR Part 11, Annex 22, and the EMA reflection paper, even if they are not personally accountable for compliance.

Skills That Will Matter in Two Years (2027 to 2028)

  • Agentic AI orchestration. Building, deploying, and governing multi-agent systems will move from novelty to expectation. Practitioners who can reason about agent architectures will command premiums.
  • Model risk and lifecycle governance. Formal capability in model risk assessment, drift management, and evidence-preserving retraining will become table stakes for regulated use cases.
  • Federated learning and privacy-preserving analytics. As multi-site RWE and collaborative research grow, federated learning skills become more important, especially in oncology and rare disease.
  • Semantic and knowledge graph engineering. Context graphs, ontologies, and knowledge graph reasoning will underpin the more sophisticated regulatory and R&D use cases.
  • Business outcome accountability. The generic “data scientist who ran a model” role fades. What replaces it is a practitioner who owns a measurable business outcome and defends the model choices that support it.

Hiring insight. The most durable talent bets in 2026 are candidates who combine one strong technical skill (pipelines, modeling, MLOps, governance) with a specific pharma domain (clinical, RWE, safety, manufacturing, commercial). Generalists without a domain anchor face the steepest career risk, and pure academics without production experience are the hardest to place effectively.

Compensation Benchmarks and Pharma-Specific Premiums

Compensation benchmarks for pharma data roles have risen sharply, in some cases twenty percent year over year for ML-adjacent roles.7 The most reliable source of ongoing benchmark data for the US market is Pharma Pay Watch, which tracks job postings across pharma and biotech and updates guides quarterly.16

US Base Salary Ranges (2026)

Role Junior Mid Senior Management
Data Scientist ~$80K ~$130K $186K+ ~$201K median16
Data Engineer / Analytics Engineer ~$95K ~$135K $160K to $215K17 $200K+
MLOps / ML Platform Engineer ~$110K $130K to $180K7 $180K to $230K $230K+
Bioinformatics / Computational Biology ~$95K ~$140K $180K to $216K18 $220K+
Data Product Manager N/A $140K to $180K $180K to $230K $230K+
AI Governance Specialist N/A $130K to $170K $170K to $220K $220K+

Company-level differences are meaningful. Among companies with multiple data science postings, AstraZeneca leads with a $222,000 median salary, followed by Pfizer at $209,000 and Genentech at $197,000.16 In bioinformatics, Eli Lilly leads at $216,000, with Recursion Pharmaceuticals at $191,000 and Novartis at $189,000.18 Big pharma base salaries are typically five to fifteen percent higher than biotech startups at equivalent levels, though startups compensate with larger equity grants and sign-on bonuses.

The “data scientist” title itself carries a premium. Having “Data Scientist” in the title commands roughly a $150,000 median versus $136,000 for biostatisticians and $109,000 for data management roles.16 Leaders should think carefully about titling, both to attract talent and to avoid title inflation that traps candidates in narrow roles.

Europe and Other Regions

European MLOps compensation is meaningfully lower than the US on base but rises quickly in specialized regulated markets. Entry-level positions start around €50,000 in most EU markets, mid-level with life sciences experience runs €70,000 to €90,000, and senior specialists in Switzerland, Germany, or the Netherlands often exceed €100,000, especially where deep regulatory or domain knowledge is required.7

Talent Sourcing Challenges Specific to Pharma

Pharma has three talent sourcing headwinds that other industries do not fully share, and leaders should design their sourcing strategies around them rather than pretending they will resolve themselves.

The Domain Overlay Problem

Most technically strong candidates come from consumer tech, finance, or general enterprise backgrounds. Very few have deep pharma domain fluency, and even fewer have both. About 70 percent of pharma hiring managers report difficulty finding candidates who combine pharmaceutical knowledge with AI skills.2 Only 20 percent of surveyed life sciences organizations say their talent is highly prepared for broad AI adoption.1 This is not a training problem the market will solve on its own.

The practical response is to hire deliberately for both directions. Some hires should be technical strong with a plan to build domain fluency through structured rotation. Others should be domain-strong with a plan to build technical fluency through paired work with senior engineers. Organizations that rely exclusively on the market to deliver hybrid candidates ready-made will end up outbid and understaffed.

The Compensation Gap With Big Tech

Even at the elevated compensation levels described above, pharma base salaries lag hyperscaler and foundation model lab compensation for the same roles by twenty to fifty percent, and total compensation lags by even more. This gap is unlikely to close. Pharma cannot compete on cash alone. It has to compete on mission, patient impact, quality of scientific problem, and long-term career pathway. Organizations that lead with those levers, and give practitioners real accountability for outcomes, retain talent better than those that try to close the gap purely on comp.

Location Constraints

Pharma has geographic center of gravity, Boston, New Jersey, Cambridge (UK), Basel, Copenhagen, and San Francisco Bay Area, among others. Modern data talent is more geographically distributed. Organizations that will not build robust remote and hybrid patterns cede a large share of the addressable talent pool. Job boards such as Built In list hundreds of pharmaceutical data engineering roles across markets like Boston and NYC, and the trend has been toward more geographic flexibility over the past two years.19

Underinvested area: workforce development. Only 29 percent of biopharma leaders and 31 percent of medtech leaders plan to use AI tools or training to improve workforce productivity, and insufficient worker skills are the single biggest barrier to AI integration in existing workflows.1 Organizations that treat internal upskilling as a secondary lever, rather than a primary one, will remain talent-constrained no matter how much they raise pay.

An Organizational Design Decision Framework

When we work with pharma leaders on data team design, we walk through a structured set of questions before recommending a shape. Below is that framework, distilled into a five-step process leaders can run themselves.

1

Map the demand landscape

List the top ten to fifteen recurring data and AI demands across the organization, tagged by domain, criticality, and regulatory status. This is not a wish list; it is the actual work you have to serve. Without this, you cannot size the team.

2

Identify the shape of the platform layer

Decide what platform capability must exist centrally to keep the team from building fifty snowflakes. This usually includes a data platform (warehouse or lakehouse), an ML platform, a model registry, and shared governance tooling. Everything else can be domain-owned.

3

Assign product ownership to durable data assets

For each of the recurring demands from step 1, decide whether it deserves a product owner. Products that are truly durable (a clinical KPI layer, a safety data mart, an RWE feature store) deserve named ownership. Everything else can be handled project-by-project.

4

Set the governance floor

Decide the minimum governance capability you need in place before the model portfolio expands further. At mid-cap and above, this includes a dedicated governance specialist, a model registry, a documented model risk process, and a review body. Do not scale AI without this floor in place.

5

Choose the reporting structure last

Only after steps 1 through 4 do you decide reporting lines. The reporting structure is a consequence of the demand pattern and the platform and product decisions, not the starting point. This is where most organizations get the sequence wrong and end up with orgs that do not match the work.

The Role Portfolio Matrix

Once the shape of the team is clear, leaders need a practical view of which roles to prioritize and in what order. The role portfolio matrix below is a simplified planning tool we use with clients to sequence hiring across the three team stages described earlier.

Role Series B Biotech Mid-Cap Pharma Large Pharma
Data Platform Lead / Data Engineer Priority 1 (Hire 1 to 2) Central team of 8 to 15 Central team of 30+
Analytics Engineer Priority 2 (Hire 1 to 2) Embed 1 to 2 per domain (5 to 10 total) Embed 2 to 4 per domain
Data Scientist (Domain) Priority 3 (Hire 1 to 2 in highest-value use case) 4 to 8 per major domain 10+ per major domain
ML Platform Engineer Defer until portfolio > 3 models Central team of 3 to 5 Central team of 15+
MLOps Engineer Defer or fractional Central team of 3 to 5 Central team of 10+
Data Product Manager Combine with function lead 3 to 5 across durable products 10 to 20 across durable products
AI Governance Specialist Fractional advisor 2+ dedicated FTEs Central function of 5 to 10
Bioinformatics / Computational Biology 1 to 2 (therapeutic-dependent) Domain-embedded, size varies Distributed across R&D
Analytics Translator / Domain SME Not a discrete role 1 per major domain Multiple per major domain

Design principle: three-layer balance. Whatever the total headcount, the ratio between platform, product, and governance layers matters more than the absolute number. Under-invest in platform and every team reinvents infrastructure. Under-invest in product and no one is accountable for durable value. Under-invest in governance and the AI portfolio becomes a compliance liability. High-performing organizations maintain a rough 2:2:1 balance across these layers at mid-cap and above.

Conclusion

The pharma data team of the future is not the pharma data team of five years ago with a few AI hires bolted on. It is a fundamentally different organizational structure, layered across platform, product, and governance, staffed with specialized roles that did not appear on the industry’s job boards until recently, and designed around the reality that domain fluency and technical depth rarely arrive in the same candidate. Leaders who take the time to design their teams around this reality, rather than reacting to individual hires, will have the durable advantage. Those who continue to hire generalists into legacy structures will spend the next three years buying and losing talent without building capability.

Sakara Digital works with pharma and biotech organizations building the kind of layered, sustainable data functions this article describes, from designing role portfolios and reporting structures to standing up governance capability that regulators can defend. If you are rethinking the shape of your data team as your AI portfolio grows, and want an independent perspective on where to start, we are happy to have that conversation.